Nonsignificant signal for fewer MACE seen in COMPASS substudy
Low-dose rivaroxaban (Xarelto) didn't improve bypass graft outcomes in a COMPASS substudy whether given alone or with aspirin, although researchers suggested a signal for benefit consistent with the main trial.